ADVERTISEMENT
Research & Development
France’s simplification bill is a “first step” to improving the country’s clinical research environment, but more could be done to drive decentralized trials and simplify processes, says Leem, the French pharmaceutical industry association.
In Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.
The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.
Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.
US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.